All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
The attention the COVID-19 pandemic drew to the biopharma industry, the ease and convenience of virtual meetings, as well as massive amounts of available capital, all led to an extraordinary year for financings in 2020. The momentum appears to be continuing, particularly with venture capital rounds.